Interview: Sandoz CEO On Biosimilars And Reshaping US Business

 
• By Kevin Grogan

Observers were left surprised by the size of the decline in US sales at Sandoz during the fourth quarter. Richard Francis, CEO of Novartis' generics division, told Scrip about plans to turn the business around in which biosimilars will figure largely.

Pottery
Reshaping Sandoz: CEO backs biosimilars to transform the business • Source: Shutterstock

More from Strategy

More from Business